The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international).

[2] The company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products.

[citation needed] Pierre Fabre is best known for its vinorelbine (Navelbine),[3][4] an anticancer drug[5] of the vinca alkaloid class.

[6][7][8] They also developed vinflunine,[9] a fluorinated vinca alkaloid derivative[10][11] available in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen.

[13] The Pierre Fabre Foundation was recognized as a public utility in 1999,[14] and its mission is to enable communities from less advanced and emerging countries, as well as those plunged into severe crisis by political or economic upheaval and/or natural disaster, to access the quality and levels of everyday health care and the widely-used drugs defined by the WHO and other organisations as essential to human health.